CD95/Fas suppresses NF-κB activation through recruitment of KPC2 in a CD95L/FasL-independent mechanism

被引:18
作者
Guegan, Jean-Philippe [1 ]
Pollet, Justine [2 ]
Ginestier, Christophe [3 ]
Charafe-Jauffret, Emmanuelle [3 ]
Peter, Marcus E. [4 ]
Legembre, Patrick [5 ]
机构
[1] Explicyte, Cours Argonne, F-33000 Bordeaux, France
[2] Univ Limoges, Technol Core Facil BISCEm, CHU Limoges, US042,Inserm,UMS CNRS 2015, Limoges, France
[3] Aix Marseille Univ, CNRS, INSERM, Inst Paoli Calmettes,CRCM Mol Oncol Equipe Labell, Marseille, France
[4] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA
[5] Univ Limoges, UMR CNRS 7276, CRIBL, INSERM 1262, Limoges, France
关键词
SIGNALING PATHWAY; NITRIC-OXIDE; SOMATIC MUTATIONS; FAS LIGAND; PROTEIN; EXPRESSION; GENE; RECEPTOR; CELLS; APOPTOSIS;
D O I
10.1016/j.isci.2021.103538
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
CD95 expression is preserved in triple-negative breast cancers (TNBCs), and CD95 loss in these cells triggers the induction of a pro-inflammatory program, promoting the recruitment of cytotoxic NK cells impairing tumor growth. Herein, we identify a novel interaction partner of CD95, Kip1 ubiquitination-promoting complex protein 2 (KPC2), using an unbiased proteomic approach. Independextly of CD95L, CD95/KPC2 interaction contributes to the partial degradation of p105 (NF-kappa B1) and the subsequent generation of p50 homodimers, which transcriptionally represses NF-kappa B-driven gene expression. Mechanistically, KPC2 interacts with the C-terminal region of CD95 and serves as an adaptor to recruit ReIA (p65) and KPC1, which acts as E3 ligase promoting the degradation of p105 into p50. Loss of CD95 in TNBC cells releases KPC2, limiting the formation of the NF-kappa B inhibitory homodimer complex (p50/p50), promoting NF-kappa B activation and the production of pro-inflammetory cytokines, which might contribute to remodeling the immune landscape in TNBC cells.
引用
收藏
页数:21
相关论文
共 50 条
  • [31] T cell activation-induced and HIV Tat-enhanced CD95(APO-1/Fas) ligand transcription involves NF-κB
    Li-Weber, M
    Laur, O
    Dern, K
    Krammer, PH
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2000, 30 (02) : 661 - 670
  • [32] Quantification of CD95-induced apoptosis and NF-κB activation at the single cell level
    Schmidt, Joern H.
    Pietkiewicz, Sabine
    Naumann, Michael
    Lavrik, Inna N.
    JOURNAL OF IMMUNOLOGICAL METHODS, 2015, 423 : 12 - 17
  • [33] ADAM15 in Apoptosis Resistance of Synovial Fibroblasts: Converting Fas/CD95 Death Signals Into the Activation of Prosurvival Pathways by Calmodulin Recruitment
    Janczi, Tomasz
    Boehm, Beate B.
    Fehrl, Yuliya
    DeGiacomo, Pangrazio
    Kinne, Raimund W.
    Burkhardt, Harald
    ARTHRITIS & RHEUMATOLOGY, 2019, 71 (01) : 63 - 72
  • [34] Innate immunity in the Grid2Lc/+ mouse model of cerebellar neurodegeneration: glial CD95/CD95L plays a non-apoptotic role in persistent neuron loss-associated inflammatory reactions in the cerebellum
    Vernet-der Garabedian, Beatrice
    Derer, Paul
    Bailly, Yannick
    Mariani, Jean
    JOURNAL OF NEUROINFLAMMATION, 2013, 10
  • [35] Activation induces apoptosis in Herpesvirus saimiri-transformed T cells independent of CD95 (Fas, APO-1)
    Broker, BM
    Kraft, MS
    Klauenberg, U
    LeDeist, F
    deVillartay, JP
    Fleckenstein, B
    Fleischer, B
    Meinl, E
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (11) : 2774 - 2780
  • [36] Fas Ligand (FasL, Apo-1L/CD95L) Expression and Clinical Outcome in Papillary Microcarcinoma and Papillary Thyroid Carcinomas with Diameter Smaller than 1.5 Centimeters
    Bayraktaroglu, T.
    Boztepe, H.
    Kapran, Y.
    Tanakol, R.
    Alagoel, F.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2010, 118 (08) : 537 - 543
  • [37] New bichalcone analogs as NF-κB inhibitors and as cytotoxic agents inducing Fas/CD95-dependent apoptosis
    Reddy, M. Vijaya Bhaskar
    Shen, Yuh-Chiang
    Yang, Jai-Sing
    Hwang, Tsong-Long
    Bastow, Kenneth F.
    Qian, Keduo
    Lee, Kuo-Hsiung
    Wu, Tian-Shung
    BIOORGANIC & MEDICINAL CHEMISTRY, 2011, 19 (06) : 1895 - 1906
  • [38] Synergistic induction of the Fas (CD95) ligand promoter by Max and NFκB in human non-small lung cancer cells
    Wiener, Z
    Ontsouka, EC
    Jakob, S
    Torgler, R
    Falus, A
    Mueller, C
    Brunner, T
    EXPERIMENTAL CELL RESEARCH, 2004, 299 (01) : 227 - 235
  • [39] CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-κB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells
    Trauzold, A
    Wermann, H
    Arlt, A
    Schütze, S
    Schäfer, H
    Oestern, S
    Röder, C
    Ungefroren, H
    Lampe, E
    Heinrich, M
    Walczak, H
    Kalthoff, H
    ONCOGENE, 2001, 20 (31) : 4258 - 4269
  • [40] T-cell factor (TCF/LEF1) binding elements (TBEs) of FasL (Fas ligand or CD95 ligand) bind and cluster Fas (CD95) and form complexes with the TCF-4 and b-catenin transcription factors in vitro and in vivo which result in triggering cell death and/or cell activation
    Xia Liu
    Yuwei Huang
    Yuanyuan Zhang
    Xiaohong Li
    Chun Liu
    Shen Huang
    Dezhi Xu
    Yang Wu
    Xiaojuan Liu
    Cellular and Molecular Neurobiology, 2016, 36 : 1001 - 1013